• O Brenet, L Lalourcey, M Queinnec, D Dupoiron, C Jayr, H Rosay, P Mavoungou, D Monnin, B Ancel, B Maget, N Louvier, and J-M Malinovsky.
• Cancer Center of Angers, Institut de Cancérologie de l’Ouest – Paul Papin, 2 rue Moll, Angers Cedex 09, France. olivier.brenet@ico.unicancer.fr
• Acta Anaesthesiol Scand. 2013 Jan 1;57(1):106-11.

BackgroundAn increasing number of immediate hypersensitivity reactions (HSR) have been reported after the use of Patent Blue V (PBV) for breast cancer surgery. This is the first study to publish prospective data with systematic allergological assessment.MethodsWe conducted a multicentre study in 10 French cancer centres for over 6 months. All patients scheduled for breast surgery with injection of PBV were included in the study. Patients were screened for past medical history, atopy, and known food and drug allergies. When suspected HSR or unexplained reactions occurred after injection of PBV, blood samples were taken, and plasma histamine and serum tryptase concentrations were measured. HSR to PBV was suggested if skin tests performed 6 weeks later were positive.ResultsNine suspected HSR to PBV were observed in 1742 patients. Skin tests were positive in six patients, giving an incidence of 0.34%. Four grade I and two grade III HSR were observed, both requiring intensive care unit treatment. Mean onset time of the reaction was 55 ± 37 min. Plasma histamine was elevated in four patients, while serum tryptase was normal. We found no risk factors associated with HSR to PBV.ConclusionAn incidence rate of one in 300 HSR to PBV was observed for patients exposed to PBV during sentinel lymph node detection. This rate is higher than rates reported after the use of neuromuscular blocking agents, latex or antibiotics.© 2012 The Authors. Acta Anaesthesiologica Scandinavica © 2012 The Acta Anaesthesiologica Scandinavica Foundation.

30 keywords...

hide…